| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000016887 |
| Receipt No. | R000019581 |
| Official scientific title of the study | A clinical study on safety and efficacy of System-i as new indwelling catheter system for hepatic arterial chemotherapy. |
| Date of disclosure of the study information | 2015/03/24 |
| Last modified on | 2018/10/04 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | A clinical study on safety and efficacy of System-i as new indwelling catheter system for hepatic arterial chemotherapy. | |
| Title of the study (Brief title) | A clinical study on safety and efficacy of System-i for hepatic arterial chemotherapy. | |
| Region |
|
|
| Condition | |||||
| Condition | hepatocellular carcinoma | ||||
| Classification by specialty |
|
||||
| Classification by malignancy | Malignancy | ||||
| Genomic information | NO | ||||
| Objectives | |
| Narrative objectives1 | The purpose of this study is to analyze the safety and efficacy of System-i as therapeutic approach for advanced hepatocellular carcinoma. |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Phase I |
| Assessment | |
| Primary outcomes | Success rate of therapy (TACE or TAI) and safety |
| Key secondary outcomes | Implantation time of system
response rate complication (liver dysfunction, stenosis of catheter) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | The new indwelling catheter system (System-i) is embedded and TACE or TAI is performed from it. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Histology/cytology-or clinically (by imaging or tumor marker) proven advanced hepatocellular carcinoma
2) ECOG performance status 0 or 1. 3) 20 years of age or older. 4) Liver function is preserved. 5) The function of the major organ is kept as satisfied by the following requirement, a) WBC (Neutrophil) >= 3,000 (1,500)/microL b) d) Cr<=2.0 *Upper limit of Normal(ULN) 6) Obtained written consent from the patient before study. |
|||
| Key exclusion criteria | 1) ECOG performance status 3.
2) Uncontrollable extra-hepatic metastasis. 3) Symptomatic or under medication cardiac disease. 4) Having other cancer. 5) Having severe dysfunction (HCC rapture, uncontrolled diabetes, heart failure, MI, Arrhythmia, etc). 6) Having possibility of pregnant or nursing. 7) Deemed inappropriate to perform the study by the physician. |
|||
| Target sample size | 15 | |||
| Research contact person | |
| Name of lead principal investigator | Seishi Nakatsuka |
| Organization | Department of Radiology, Keio University, school of medicine |
| Division name | Department of Radiology |
| Address | Shinanomachi 35, Shinjuku-ku, Tokyo |
| TEL | 03-3353-1211 |
| nakatsuk@a2.keio.jp | |
| Public contact | |
| Name of contact person | Yuuta Abe |
| Organization | Department of surgery, Keio University, school of medicine |
| Division name | Department of Surgery |
| Address | Shinanomachi 35, Shinjuku-ku, Tokyo |
| TEL | 03-3353-1211 |
| Homepage URL | |
| abey3666@gmail.com | |
| Sponsor | |
| Institute | Keio University School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000019581 |